The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma

医学 浆液性液体 靶向治疗 肿瘤科 生物标志物 背景(考古学) 恶性肿瘤 内科学 浆液性癌 癌症研究 癌症 卵巢癌 生物 生物化学 古生物学
作者
Karen L. Talia,Natalie Banet,Natália Buza
出处
期刊:Pathology [Elsevier BV]
卷期号:55 (1): 8-18 被引量:16
标识
DOI:10.1016/j.pathol.2022.11.004
摘要

Human epidermal growth factor receptor 2 (HER2) is a prognostic biomarker and therapeutic target in carcinomas of the breast, stomach and colon. In 2018, clinical trial data confirmed the prognostic and predictive role of HER2 in uterine serous carcinoma, with a demonstrated survival benefit from combined chemotherapy and anti-HER2 targeted therapy in patients with advanced or recurrent disease. Approximately one-third of uterine serous carcinomas demonstrate HER2 protein overexpression and/or gene amplification and HER2 immunohistochemistry, supplemented by in situ hybridisation in equivocal cases, is fast becoming a reflex ancillary test at time of diagnosis. The potential role of HER2 in gynaecological tumours other than uterine serous carcinoma is yet to be firmly established. With the advent of personalised medicine, routine tumour sequencing and pursuit of targeted therapies, this is a field currently under active investigation. Emerging data suggest triaging endometrial carcinomas for HER2 analysis based on molecular classification may be superior to histotype-based testing, with copy-number high/p53 mutant tumours enriched for HER2 overexpression or amplification. Accordingly, many carcinosarcomas and a subset of clear cell and high-grade endometrioid carcinomas may be eligible for HER2 targeted therapy, although any clinical benefit in this context is currently undefined. For ovarian carcinomas, combined data support the role of HER2 as a prognostic biomarker, however its use as a therapeutic target is yet to be elucidated through clinical trials. In the cervix, reported rates of HER2 overexpression vary and are generally low, and currently there is insufficient evidence to justify routine HER2 testing in this context. Limited data suggest HER2 holds promise as a prognostic and predictive biomarker in vulvar Paget disease. Future clinical trials, with pathologist input to develop and refine site-specific scoring criteria, are required to establish what role HER2 might play more broadly in gynaecological cancer care.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
lqz07完成签到,获得积分10
1秒前
影子发布了新的文献求助10
1秒前
赘婿应助蓝桉采纳,获得10
1秒前
2秒前
多年以后完成签到,获得积分10
2秒前
goldNAN发布了新的文献求助10
2秒前
激动的访文完成签到,获得积分10
2秒前
NexusExplorer应助咩咩采纳,获得10
2秒前
蓝莓松饼完成签到,获得积分20
2秒前
2秒前
未来的枕头完成签到,获得积分10
3秒前
3秒前
4秒前
4秒前
4秒前
爱你完成签到,获得积分10
4秒前
lxy发布了新的文献求助10
4秒前
薛蹇发布了新的文献求助10
5秒前
5秒前
5秒前
5秒前
小余同学发布了新的文献求助10
6秒前
烟花应助rengar采纳,获得10
6秒前
7秒前
7秒前
7秒前
wasd完成签到,获得积分20
7秒前
mumu发布了新的文献求助10
8秒前
8秒前
Orange应助晨陌兮客采纳,获得10
8秒前
qyzhu发布了新的文献求助10
8秒前
Lin发布了新的文献求助10
8秒前
9秒前
9秒前
xixi发布了新的文献求助20
9秒前
能干的邹发布了新的文献求助10
9秒前
Lynn发布了新的文献求助10
9秒前
坚果发布了新的文献求助10
10秒前
MHX发布了新的文献求助10
11秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970632
求助须知:如何正确求助?哪些是违规求助? 3515261
关于积分的说明 11177794
捐赠科研通 3250448
什么是DOI,文献DOI怎么找? 1795314
邀请新用户注册赠送积分活动 875781
科研通“疑难数据库(出版商)”最低求助积分说明 805073